Under a tenth of individuals who could benefit from obesity jabs including Wegovy are able to get them, caution the global health agency as it issues its first guidance on the medications.
Given more than one billion people worldwide currently classified as obese, it is urging increased and just availability to these injectable treatments.
Per forecasts, more than two billion will be living with obesity by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a chronic disease that can be managed with holistic and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are major hurdles to universal access to the treatments that can aid individuals in losing significant body mass, says the organization.
Weight-Loss Drug Shortage
Even in the current most favorable outlook, the production of GLP-1 therapies could only cover around 100 million people – under 10% of the global need, as stated by the health organization.
The advice calls on countries and companies to expand access, via approaches like patent sharing.
A patent on the active ingredient – the primary ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Jabs Operate
The injections imitate a natural hormone to delay gastric emptying, reduce hunger and enhance satiety so individuals consume fewer calories.
People typically see weight reduction in the initial weeks of beginning the regular doses.
Research suggests people may see weight return within a year of halting the medication, because their normal appetite resume.
Being carrying excess weight raises your risk for experiencing medical conditions, such as diabetes, heart disease, brain attack, and certain malignancies.
Excess weight concerns people in every country and was linked to millions of fatalities worldwide in 2024, as per the health agency.
